Stoke Therapeutics (NASDAQ:STOK) Announces Earnings Results

Stoke Therapeutics (NASDAQ:STOK) issued its quarterly earnings data on Tuesday. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.05, Zacks reports. The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%.

Stoke Therapeutics Stock Up 0.2 %

Shares of Stoke Therapeutics stock traded up $0.02 on Thursday, hitting $13.27. 280,079 shares of the company were exchanged, compared to its average volume of 760,807. Stoke Therapeutics has a 1-year low of $3.77 and a 1-year high of $17.58. The stock has a market capitalization of $698.64 million, a price-to-earnings ratio of -6.09 and a beta of 0.95. The company has a 50-day moving average price of $13.24 and a 200 day moving average price of $13.70.

Insider Buying and Selling

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now directly owns 8,906,181 shares in the company, valued at $125,131,843.05. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 11.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

STOK has been the topic of a number of recent analyst reports. Wedbush reiterated an “outperform” rating and set a $17.00 target price on shares of Stoke Therapeutics in a research report on Thursday, July 11th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, Leerink Partners initiated coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective for the company. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $20.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.